Enbrel Ankylosing Spondylitis sBLA Clears FDA Cmte.; Modifying Claim Next

Sponsors seeking a disease-modifying claim for an ankylosing spondylitis indication should assess the radiographic progression of the disease, FDA's Arthritis Advisory Committee agreed during its June 24 review of Amgen/Wyeth's Enbrel